Should You Buy UPS While It's Below $90?

United Parcel Service (UPS) shares have declined approximately 30% year-to-date, with Q2 revenue falling nearly 3% to $21.2 billion and net income down almost 9%, primarily due to the repeal of the de minimis exemption impacting high-margin China-to-U.S. express routes and increased competition. In response, UPS is implementing an "Efficiency Reimagined" plan, including significant job cuts and facility closures, while strategically pivoting to higher-margin segments like healthcare logistics and growing international express lanes. Despite near-term headwinds, the company's current valuation, with a P/E of 13 and a 7.5% dividend yield, positions it as a potential value play for long-term investors.

Analysis

United Parcel Service (UPS) is navigating significant operational and competitive headwinds, reflected in a 30% year-to-date share price decline. The company's second-quarter results highlight these challenges, with revenue falling nearly 3% to $21.2 billion and net income declining almost 9%. A key driver of this weakness is the repeal of the de minimis exemption, which has caused a 35% year-over-year drop in volume on the high-margin China-to-U.S. express route. Concurrently, UPS is losing market share to the expanding in-house delivery networks of Amazon and Walmart, as well as to nimbler regional couriers. In response, management is executing its "Efficiency Reimagined" plan, which involves cutting 20,000 jobs and closing 73 facilities to improve its cost structure. Strategically, UPS is pivoting towards higher-margin business by reducing its exposure to low-margin clients like Amazon and expanding into new growth areas. This pivot is evidenced by a 22.4% increase in China-to-rest-of-world shipments and a near-doubling of India-to-Europe volumes, alongside a significant push into healthcare logistics, underscored by the $1.6 billion acquisition of Andlauer Healthcare Group. Despite near-term uncertainty, the company's valuation appears compressed, trading at a P/E ratio of 13, below its historical average, and offering a substantial 7.5% dividend yield, which frames the stock as a potential value proposition for patient investors.

Key Decisions for Investors

• Given the stock's valuation at a P/E of 13 and a 7.5% dividend yield, long-term value and income-focused investors could view the current share price as an attractive entry point, provided they can tolerate near-term volatility.
• Investors should closely monitor the progress of the "Efficiency Reimagined" plan for evidence of margin stabilization and track growth in strategic segments like healthcare and non-U.S. international routes to validate the company's turnaround strategy.
• It is crucial to weigh the potential for a value rebound against significant risks, including sustained pressure on high-margin routes from trade policy and intensifying competition from major retailers and regional carriers.